Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. (RVMD) is a clinical-stage biotechnology company pioneering targeted therapies for cancers driven by RAS mutations. This page serves as the definitive source for verified news and developments related to the company's precision oncology programs.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and scientific advancements in RAS pathway inhibition. Our curated collection includes press releases on drug discovery breakthroughs, partnership announcements, and peer-reviewed research findings.
Key focus areas include updates on the company's RAS(ON) inhibitor portfolio, mTOR signaling developments, and strategic collaborations advancing cancer treatment innovation. All content is vetted for accuracy and relevance to provide reliable insights into RVMD's evolving pipeline.
Bookmark this page for structured access to essential updates about Revolution Medicines' progress in addressing unmet needs in oncology through its evolution-inspired therapeutic approaches.
Revolution Medicines (Nasdaq: RVMD) reported Q3 2025 financial results and clinical progress on RAS(ON) inhibitors.
Clinical: RASolute 302 enrollment for daraxonrasib in previously treated PDAC is winding down with an expected data readout in 2026; RASolute 303 (first-line metastatic PDAC) remains on track to start in 2025; RASolute 304 (adjuvant resectable PDAC) has been initiated. Daraxonrasib holds FDA Breakthrough Therapy, Orphan Drug designation and a Commissioner’s National Priority Voucher. New trials for zoldonrasib, elironrasib and RMC-5127 are planned in 2026–2026 Q1.
Financial: Cash and marketable securities were $1.93B at Sept 30, 2025, including a $250M royalty tranche and $1.75B committed; Q3 R&D $262.5M, G&A $52.8M, net loss $305.2M; reiterated FY2025 GAAP net loss guidance of $1.03B–$1.09B. Company announced senior commercial and development hires and held a webcast on Nov 5, 2025.
Revolution Medicines (Nasdaq: RVMD) announced that CEO and chairman Mark A. Goldsmith, M.D., Ph.D. will participate in two investor conference fireside chats in November 2025.
Event details: Guggenheim Healthcare Innovation Conference fireside chat on Tuesday, November 11, 2025 at 9:00 a.m. ET, and Jefferies Global Healthcare Conference fireside chat on Tuesday, November 18, 2025 at 9:30 a.m. GMT. Live webcasts and archived replays will be available at the company investor events page, with replay access for at least 14 days.
Revolution Medicines (Nasdaq: RVMD) will report third-quarter 2025 financial results on Wednesday, November 5, 2025 after market close.
The company said a senior management webcast will begin at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and provide a corporate update. Investors can listen live or access the archived webcast at https://ir.revmed.com/events-and-presentations. A replay will be available on the company website for at least 14 days following the live event.
Revolution Medicines (NASDAQ: RVMD) announced on October 27, 2025 that the U.S. FDA granted Orphan Drug Designation to daraxonrasib for the treatment of pancreatic cancer.
Daraxonrasib is a RAS(ON) multi-selective inhibitor currently being studied in a global Phase 3 RASolute 302 trial for second-line metastatic pancreatic ductal adenocarcinoma (PDAC). The company also plans two additional Phase 3 trials: one for first-line metastatic PDAC and one for adjuvant treatment in resectable PDAC.
The designation makes daraxonrasib eligible for incentives, including tax credits for clinical trial costs, exemption from certain FDA fees, and up to seven years of market exclusivity if approved.
Revolution Medicines (Nasdaq: RVMD) reported updated clinical results for elironrasib in previously treated KRAS G12C NSCLC patients who had received prior KRAS(OFF) G12C inhibitors, highlighted at the AACR-NCI-EORTC Symposium (Oct 23-25, 2025).
As of the Aug 4, 2025 cutoff (n=24), elironrasib at 200 mg BID showed a confirmed objective response rate 42% (95% CI: 22-63), disease control rate 79%, median duration of response 11.2 months, median PFS 6.2 months, and 12-month OS rate 62%. In July 2025 elironrasib received Breakthrough Therapy Designation for certain KRAS G12C NSCLC patients.
Revolution Medicines (Nasdaq: RVMD) announced the U.S. FDA granted a non-transferrable Commissioner's National Priority Voucher (CNPV) for daraxonrasib (RMC-6236), its RAS(ON) multi-selective inhibitor.
Daraxonrasib is in two global Phase 3 trials: RASolute 302 (previously treated metastatic pancreatic ductal adenocarcinoma) and RASolve 301 (previously treated metastatic non-small cell lung cancer). The company noted a expected data readout from RASolute 302 in 2026 and said it is evaluating the voucher's impact without changing previously disclosed timelines.
Revolution Medicines (NASDAQ:RVMD), a late-stage clinical oncology company, has announced significant leadership appointments to strengthen its development and commercial capabilities. Dr. Alan Sandler joins as Chief Development Officer, bringing extensive oncology expertise from his previous roles at ALX Oncology, Mirati Therapeutics, and Genentech.
The company has also appointed Alicia Gardner as SVP and General Manager for the U.S. region and Gerwin Winter as SVP and General Manager for Europe. These appointments align with Revolution Medicines' preparation for potential approvals and commercial launches of daraxonrasib for RAS-driven cancers, including pancreatic ductal adenocarcinoma.
Revolution Medicines (NASDAQ:RVMD) announced promising clinical results for daraxonrasib in treating pancreatic ductal adenocarcinoma (PDAC). The data supports the initiation of RASolute 303, a global Phase 3 registrational trial in Q4 2025.
Key findings include:
- In second-line treatment, daraxonrasib showed 35% objective response rate and 13.1 months median overall survival for RAS G12X mutation patients
- First-line monotherapy demonstrated 47% objective response rate with 89% disease control rate
- Combination therapy with GnP achieved 55% objective response rate with 90% disease control rate
The upcoming Phase 3 trial will evaluate daraxonrasib both as monotherapy and in combination with GnP chemotherapy for first-line metastatic PDAC treatment.
Revolution Medicines (Nasdaq: RVMD) reported Q2 2025 financial results and corporate updates, highlighting significant progress in its oncology pipeline. The company's lead drug daraxonrasib received FDA Breakthrough Therapy Designation for PDAC treatment, with Phase 3 trial RASolute 302 expected to complete enrollment this year. A major financial milestone includes securing a $2 billion flexible funding agreement with Royalty Pharma.
The company reported Q2 2025 financial results with a net loss of $247.8 million (vs $133.2 million in Q2 2024), R&D expenses of $224.1 million, and G&A expenses of $40.6 million. Cash position stands at $2.1 billion, including $250 million from Royalty Pharma. Full-year 2025 projected GAAP net loss is estimated between $1.03-1.09 billion.
Multiple clinical programs are advancing, including elironrasib's FDA Breakthrough Therapy Designation for NSCLC treatment and promising developments with zoldonrasib for KRAS G12D mutations.
Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, will release its Q2 2025 financial results on August 6, 2025, after market close.
The company's senior management will host a webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss quarterly results and provide corporate updates. The webcast will be accessible through the company's investor relations website, with a replay available for at least 14 days following the live presentation.
FAQ
What is the current stock price of Revolution Medicines (RVMD)?
What is the market cap of Revolution Medicines (RVMD)?
